1 Safety of hyperbaric oxygen therapy in patients with heart

2 failure: A retrospective review

- 4 Simone Schiavo ^{1,2}, Connor T. A. Brenna ¹, Lisa Albertini ³, George Djaiani ^{1,2},
- 5 Anton Marinov 1,4, Rita Katznelson 1,2,4
- 6
- 7 ¹ Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON, Canada
- 8 ² Hyperbaric Medicine Unit, Toronto General Hospital, Toronto, ON, Canada;
- 9 <u>hyperbaricmedicineunit@uhn.ca</u> Department of Anesthesia and Pain Management, University Health Network,
- 10 Toronto, ON, Canada
- ³ Department of Medicine, Division of Cardiology, University of Toronto, Toronto, ON, Canada
- 12 ⁴Rouge Valley Hyperbaric Medical Center, Scarborough, ON, Canada
- 13
- 14 Corresponding author: Rita Katznelson, <u>rita.katznelson@uhn.ca</u>

15 Abstract

16	Background: Hyperbaric oxygen therapy (HBOT) has several hemodynamic effects including
17	increases in afterload (due to vasoconstriction) and decreases in cardiac output. This, along
18	with rare reports of pulmonary edema during emergency treatment, has led providers to
19	consider HBOT relatively contraindicated in patients with reduced left ventricular ejection
20	fraction (LVEF). However, there is limited evidence regarding the safety of elective HBOT in
21	patients with heart failure (HF), and no existing reports of complications among patients with
22	HF and preserved LVEF. We aimed to retrospectively review patients with preexisting diagnoses
23	of HF who underwent elective HBOT, to analyze HBOT-related acute HF complications.
24	Methods: Research Ethics Board approvals were received to retrospectively review patient
25	charts. Patients with a history of HF with either preserved ejection fraction (HFpEF), mid-range
26	ejection fraction (HFmEF), or reduced ejection fraction (HFrEF) who underwent elective HBOT
27	at two Hyperbaric Centers (Toronto General Hospital, Rouge Valley Hyperbaric Medical Centre)
28	between June 2018 and December 2020 were reviewed.
20	D esults, Twenty three notion to with a bistory of UE underwart UDOT, completing on everyons of
29	Results: Twenty-three patients with a history of HF underwent HBOT, completing an average of
30	39 (range 6 – 62) consecutive sessions at 2.0 atmospheres absolute (ATA) (n=11) or at 2.4 ATA
31	(n=12); only two patients received fewer than 10 sessions. Thirteen patients had HFpEF (mean
32	LVEF 55 \pm 7%), and seven patients had HFrEF (mean LVEF 35 \pm 8%) as well as concomitantly
33	decreased right ventricle function (n=5), moderate/severe tricuspid regurgitation (n=3), or
34	pulmonary hypertension (n=5). The remaining three patients had HFmEF (mean LVEF 44 \pm 4%).
35	All but one patient was receiving fluid balance therapy either with loop diuretics or dialysis.

36	Twenty-one patients completed HBOT without complications. We observed symptoms
37	consistent with HBOT-related HF exacerbation in two patients. One patient with HFrEF (LVEF
38	24%) developed dyspnea attributed to pulmonary edema after the fourth treatment, and later
39	admitted to voluntarily holding his diuretics before the session. He was managed with
40	increased oral diuretics as an outpatient, and ultimately completed a course of 33 HBOT
41	sessions uneventfully. Another patient with HFpEF (LVEF 64%) developed dyspnea and
42	desaturation after six sessions, requiring hospital admission. Acute coronary ischemia and
43	pulmonary embolism were ruled out, and an elevated BNP and normal LVEF on echocardiogram
44	confirmed a diagnosis of pulmonary edema in the context of HFpEF. Symptoms subsided after
45	diuretic treatment and the patient was discharged home in stable condition, but elected not to
46	resume HBOT.
47	Conclusions : Patients with HF, including HFpEF, may develop HF symptoms during HBOT and
48	warrant ongoing surveillance. However, these patients can receive HBOT safely after

49 optimization of HF therapy and fluid restriction.

51 Introduction

52 Hyperbaric oxygen therapy (HBOT) is an evidence-based intervention used to treat a 53 variety of elective conditions, in addition to its role as an emergency treatment for carbon monoxide toxicity, decompression sickness, and arterial gas embolism (S1 Table) (1). The safety 54 55 profile of HBOT is very favorable: although minor side effects related to increased environmental 56 pressure and/or systemic hyperoxia can occur (e.g., claustrophobia, transient myopia, or middle ear barotrauma) (2-4), serious treatment complications (e.g., seizures, pulmonary oxygen 57 58 toxicity, or pulmonary edema) are extremely rare (5). Anectodical evidence has suggested that patients with decreased left ventricular ejection fraction (LVEF) may be at an increased risk of 59 acute heart failure (HF) during HBOT (6). Although this risk has not been substantiated by robust 60 evidence, left ventricular (LV) systolic dysfunction has traditionally been considered a relative 61 contraindication to HBOT (6). 62

63 Several hemodynamic changes are known to occur during and immediately after 64 hyperbaric oxygen exposure (7). HBOT increases cardiovascular afterload, with associated 65 increases in systolic and mean arterial blood pressure (BP), while cardiac output (CO) decreases 66 due primarily to a decrease in heart rate (HR). Previous literature characterizing the effect of 67 HBOT on CO is summarized in Table 1.

68

Table 1. Previous studies characterizing the effect of hyperbaric oxygen therapy on cardiac
 output.

Study	CO change	ΑΤΑ
-------	-----------	-----

	(% compared to baseline)	
Whalen, 1965 (8)	-13	3.04
Pisarello, 1987 (9)	-8	3.0
	-15	2.5
Pelaia, 1992 (10)	-17	2.2
McMahon, 2002 (11)	-10	3.0
Weaver, 2009 (12)	-18	2.5
	-16	3.0

Changes in cardiac output associated with hyperbaric oxygen therapy among previous reports.
 Abbreviations: CO = cardiac output, ATA = absolute atmospheres of pressure.

Numerous mechanisms for the effect of HBOT on CO have been suggested (13, 14) 73 74 although this effect predominately results from HBOT-induced vasoconstriction, the physiological protective response to extremely high arterial partial pressures of oxygen (7). These 75 hemodynamic changes appear to be well tolerated in patients without preexisting cardiac disease 76 (15, 16). However, there is limited evidence regarding the applicability of HBOT in patients with 77 HF and reduced ejection fraction (HFrEF) and, furthermore, no data on patients with HF with 78 preserved ejection fraction (HFpEF) or HF with mid-range ejection fraction (HFmEF). We aimed 79 to examine the safety of HBOT for patients with preexisting diagnoses of HF. 80

81

83 Methods

84 Study design

This is a retrospective longitudinal cohort study of patients with HF who underwent elective HBOT between June 2018 and December 2020 in two Hyperbaric Medicine Centers in Ontario, Canada (Toronto General Hospital, Toronto; Rouge Valley Hyperbaric Medical Centre, Scarborough). Institutional Research Ethics Board approvals (CAPCR ID: 19-5081.1; IRB ID:2023-3194-14092-4) were obtained for study team members to collect data from medical records (last access to data on March 31, 2023; all authors but one (SS) did not have access to information that could identify individual participants during or after data collection).

92

93 **Definitions**

In accordance with the Canadian Cardiovascular society guidelines (17), HF was defined 94 as a clinical syndrome in which abnormal heart function results in (or increases the risk of) clinical 95 symptoms and signs of reduced cardiac output and/or pulmonary or systemic congestion either 96 97 at rest or with stress. Chronic HF represents the persistent and progressive nature of the disease, whereas acute HF is defined as a change in HF signs and symptoms resulting in the need for 98 urgent therapy. Recent guidelines proposed a new and revised classification of HF according to 99 100 LVEF (18-20), which includes: (i) HF with preserved ejection fraction (HFpEF) = LVEF \geq 50%; (ii) HF 101 with mid-range ejection fraction (HFmEF) = LVEF 41-49%; and (iii) HF with reduced ejection 102 fraction (HFrEF) = LVEF \leq 40%.

103 HFpEF is diagnosed in patients with signs and symptoms of HF as the result of high LV 104 filling pressure, despite preserved LVEF (\geq 50%) (18). These patients also display normal LV 105 volumes and an abnormal diastolic filling pattern (diastolic dysfunction) (18, 21); therefore, 106 HFpEF is sometimes referred to as diastolic heart failure (22, 23).

107

108 Participants and data collection

109 We included all patients 18 years of age or older with a history of HF, regardless of EF, 110 undergoing elective HBOT during the study period. To further categorize these patients, LVEF 111 measurements via echocardiography were identified (where available) and used to stratify 112 patients into three groups: (i) HFpEF = LVEF \geq 50%; (ii) HFmEF = LVEF 41 – 49%; and (iii) HFrEF = 113 LVEF \leq 40% (17).

Each patient's demographic variables, past medical history, and medications were extracted from medical charts. Additional data extracted during the treatment period included HBOT indication, treatment pressure, total number of HBOT sessions, and adverse events associated with HBOT, including subjective symptoms reported by the patients and reported into the medical chart. All patients described in the study provided written consent to undergo HBOT for a clinical indication approved by Health Canada.

120

121 Hyperbaric oxygen therapy protocol

122 Conventional HBOT protocols were utilized in the treatment of all patients, as previously 123 described (15): these included the administration of 100% oxygen at 2.0 or 2.4 atmospheres

absolute (ATA) for 90 minutes, with 1 - 2 air breaks (0.21 fraction of inspired O₂ at the same ATA) 124 125 per session, five times weekly, either in a mono-place chambers (Sechrist 3600H and Sechrist 4100H, Sechrist Industries Inc., Anaheim, CA, USA; PAH-S1-3200, Pan-America Hyperbarics Inc., 126 127 Plano, TX, USA; Sigma 36, Perry Baromedical, Riviera Beach, Fl, USA) or through a plastic hood in 128 the multi-place chamber (rectangular Hyperbaric System, Fink Engineering PTY-LTD, Warana, Australia). Standard monitoring included measurements of systolic (SAP), diastolic (DAP), and 129 130 mean (MAP) blood pressure (BP), heart rate (HR), and peripheral oxygen saturation (SpO2) 131 assessed during a five-minute period preceding and following each HBOT session. BP was 132 measured non-invasively using an upper arm cuff and automated sphygmomanometer (Connex VSM 6000, WelchAllyn—Hill-Rom, New York, NY, USA) with the patient in a sitting or semi-sitting 133 134 position.

135

136 **Outcomes**

The objective of this study was to evaluate the safety of HBOT among patients with known HF. The primary outcome was to describe any clinical signs or symptoms of acute heart failure occurring during and immediately after HBOT. Secondary outcomes included other treatment complications, assessed as the number of patients experiencing HBOT-related adverse or serious adverse events, such as barotrauma, oxygen toxicity (either central nervous system or pulmonary), ocular changes, or confinement anxiety.

143

144 **Statistical analysis**

- 145 Qualitative data including patient demographics and past medical history characteristics
- 146 were summarized using descriptive statistics. Continuous data were expressed as means ±
- 147 standard deviations.

148 **Results**

149 Clinical data

- 150 During the study period, 23 patients with a documented diagnosis of HF received elective
- 151 HBOT. Table 2 summarizes patients' details and HBOT characteristics.

152 Table 2. Baseline demographics, comorbidities, and medications of the patient cohort.

	n= 23
Age (years)	70 ± 12
Body Mass Index (kg/m ²)	31 ± 11
Female	8
Comorbidities	
History of hypertension	21
Baseline Heart Failure classification:	13
Preserved EF (LVEF \geq 50%)	3
Mid-range EF (LVEF 41-49%)	7
Reduced EF (LVEF ≤ 40%)	/
Coronary artery disease	14
Left ventricular hypertrophy	7
Heart valvular disease	6
Diastolic dysfunction	7
Atrial fibrillation	9
Peripheral vascular disease	11
Diabetes mellitus:	
Type 1	2
Type 2	16
Chronic obstructive pulmonary disease	5
Restrictive lung disease	0
Smoking status:	0
Never	15
Current	2
Past	_
	6
Renal insufficiency Dialysis	14 5
Medications	3
ACEi/ARBs	11
B-blockers	15
Calcium channel blockers	13
Diuretics	13
Vasodilators	18
HBOT Pressure (2.4 ATA)	12

Descriptive analysis of patients included in this study (n = 23). Abbreviations: EF = ejection fraction, LVEF = left ventricular ejection fraction, ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, ATA = absolute atmospheres of pressure.

156

The mean patient age was 70 \pm 12 years and 15 (65%) were male. A majority of patients 157 had comorbid diagnoses of hypertension (21; 91%), type 2 diabetes (16; 70%), and/or coronary 158 artery disease (14; 61%). At baseline, 13 (57%), 3 (13%), and 7 (30%) patients had HF categorized 159 160 as HFpEF (\geq 50%), HFmEF (41 – 49%) and HFrEF (\leq 40%), respectively. All 10 patients with HFrEF 161 or HFmEF (100%) had a prior hospitalization for HF, compared to 7 out of 13 (54%) of patients 162 with HFpEF. Overall, 11 (48%) were receiving treatment with ACEi/ARBs, 15 (65%) with 163 betablockers, and 18 (78%) with diuretics, including 16 with loop diuretics, one with thiazide 164 diuretics and one with potassium-sparing diuretics. Five (22%) patients were on dialysis, including 165 one concurrently receiving diuretics, and only one patient with HFpEF was not receiving any diuretic nor dialysis. Pre-HBOT, all but one patient underwent a transthoracic echocardiography 166 167 (Table 2) in addition to a clinical assessment which excluded signs of acute heart failure prior to 168 compression.

169

170 **HBOT characteristics**

Twelve patients received HBOT at a pressure of 2.4 ATA; the remaining 11 patients underwent treatment at 2.0 ATA. Collectively, the 23 patients described in this study completed a total of 906 HBOT sessions. Each patient underwent an average of 39 ± 17 treatments, and half

- of them (434; 48%) were delivered at 2.4 ATA. Table 3 summarizes details of treatment for each
- 175 patient.

176 **Table 3. Hyperbaric oxygen therapy details.**

Patient #	LVEF (%)	ΑΤΑ	Total number of	Indication
		prescribed	treatments	
1	34	2.4	26	AI LL
2	54	2.4	60	DFU
3	66	2.4	35	AI LL
4	33	2.4	35	STRI-RC
5	55	2.4	23	ORN (jaw)
6	50	2.4	58	DFU
7	52	2.4	50	DFU
8	45	2.4	40	AI LL
9	31	2.0	49	DFU
10	50	2.4	60	СРНҮХ
11	24	2.4	33 *	СРНҮХ
12	64	2.4	6	DFU
13	40	2.4	8	СРНҮХ
14	52	2.0	50	DFU
15	56	2.0	60	DFU
16	48	2.0	42	DFU
17	32	2.0	30	DFU
18	51	2.0	62	DFU
19	30	2.0	17	DFU
20	50	2.0	36	DFU
21		2.0	60	STRI-RP
22	50	2.0	41	СРНҮХ
23	52	2.0	25	DFU

177	Treatment details for each patient included in the cohort (n = 23), including LVEF, HBOT
178	exposure pressure, number of sessions, indications for HBOT, and treatment center.
179	Abbreviations: HBOT = hyperbaric oxygen therapy; ATA = absolute atmospheres of pressure;
180	LVEF = left ventricle ejection fraction; AI LL = arterial insufficiency – lower extremity; DFU =
181	diabetic foot ulcer; STRI = soft tissue radiation injury; RC = radiation cystitis; RP = radiation
182	proctitis; ORN = osteoradionecrosis; CPHYX = calciphylaxis. *Patient #11: 7 out of the 33
183	sessions were at 2.0 ATA, and the remainder at 2.4 ATA.
184	

185

186 Acute cardiovascular complications

We observed symptoms consistent with HBOT-related HF in two patients (2/23, 9%). One 187 patient with HFrEF (LVEF 24%) developed dyspnea after their fourth treatment for a diabetic foot 188 ulcer. He had a history of hypertension, non-ischemic dilated cardiomyopathy, left ventricle 189 190 hypertrophy, moderate pulmonary hypertension, mild tricuspid regurgitation, moderate diastolic 191 disfunction, atrial fibrillation, peripheral vascular disease, obesity, diabetes, and kidney failure (not on dialysis). A routine random B-type Natriuretic peptide (BNP) collected one month before 192 HBOT was 402 g/mL (Lab reference range: <= 99.9 pg/mL). Following HBOT, examination revealed 193 an increased work of breathing and crackles consistent with pulmonary edema, without 194 peripheral oxygen desaturation. In the emergency department, his BNP was measured at 1580 195 196 pg/ml, and he was managed with increased oral diuretics but did not require hospitalization. This 197 patient later disclosed that he had voluntarily held his diuretics before the treatment to avoid

needing to urinate while inside the hyperbaric chamber. He subsequently continued HBOT,completing a total of 33 sessions without further complication.

A second patient, with HFpEF (LVEF 74%), developed dyspnea and desaturation after the 200 201 sixth treatment session (also for a diabetic foot ulcer), ultimately requiring hospital admission. He had a history of hypertension, type 2 diabetes on insulin, obesity, coronary artery disease with 202 203 HFpEF, and mild diastolic dysfunction (on double diuretic therapy). His hypertension was reported as well controlled on dual therapy (nifedipine and telmisartan), but a review of his BP 204 measured before and after each session revealed a consistently increased SAP (mean 155 ± 11 205 206 mmHg) and normal DAP (77 ± 4 mmHg) before each treatment, and both an increased SAP (170 \pm 3 mmHg) and DAP (86 \pm 10 mmHg) following each treatment. During the acute episode 207 208 following his sixth HBOT session, acute coronary ischemia and pulmonary embolism were clinically excluded. A diagnosis of pulmonary edema in the context of HFpEF was made on the 209 210 basis of an elevated BNP (143 pg/mL), pulmonary congestion identified through bedside lung 211 ultrasound and chest X-ray, and normal LVEF with the presence of diastolic dysfunction on 212 transthoracic echocardiogram. The patient's symptoms subsided after administration of an 213 intravenous loop diuretic (furosemide), and he was discharged home in stable condition. 214 However, he elected not to resume HBOT. Three years later, he died of an unrelated oncologic 215 pathology.

216

No acute cardiovascular complications were observed among the other 21 patients.

217

218 **Other complications**

219	A total of seven non-serious adverse events were recorded: five instances of middle-ear
220	barotrauma, and two of confinement anxiety. In each case, appropriate coaching and treatment
221	were provided, and all patients continued HBOT without further complication.

222

223 **Discussion**

In this study we investigated whether patients with a history of HF can safely receive HBOT. Two patients in our cohort (9%) experienced acute symptoms of heart failure in relation to HBOT. One had a history of HFrEF, which portends a theoretical risk with respect to HBOT. The other had a history of HFpEF, which has not been previously reported to increase cardiac risks of HBOT.

229

230 Heart failure with reduced ejection fraction

HBOT is known to negatively impact cardiac output (CO), even among healthy patients (24). The decreased CO, along with an increased afterload resulting from systemic vascular resistance, has been hypothesized to be the cause of pulmonary edema reported in patients with reduced EF (6). In our cohort, among seven patients with HFrEF, only one developed signs of acute heart failure following HBOT. This patient had a severely impaired LVEF below 30% and he was receiving treatment with loop diuretics, although for two days he had been withholding his morning doses. With appropriate coaching and therapy optimization (an increase in the dose of his loop diuretic), he continued HBOT and was able to complete 29 additional sessions without
further complication. Our experience with these seven patients indicates that HBOT may
exacerbate pulmonary congestion in patients with reduced ejection fraction, but also supports
the feasibility of cautious treatment with close monitoring in this population after optimization
of diuretic therapy. Interestingly, more recent studies have analyzed the long-term effects of
HBOT on myocardial function, and paradoxically support a possible positive effect of HBOT on
LVEF and other echocardiographic measures over longer time horizons (25-27).

245

246 Heart failure with preserved ejection fraction

One of the 13 patients with HFpEF in our cohort developed acute signs of heart failure 247 after six HBOT sessions. He had a history of hypertension, previous admission for heart failure, 248 echocardiographic evidence of diastolic dysfunction, and ongoing treatment with thiazide 249 250 diuretics but not loop diuretics. His consistently increased SAP and DAP post-sessions may 251 suggest a marked increase in afterload during and after each session (15), and increased afterload is a well-known effect of HBOT which contributes to decreases in CO (6, 12). Further, there is 252 253 evidence that hyperoxia increases LV end-diastolic pressure (LVEDP), and it is associated with disturbances of both early and late phases of LV filling in patients with and without HF (28). As a 254 result, it is possible that a combination of increased afterload and impaired ventricular relaxation 255 in the context of preexisting diastolic disfunction might represent the mechanism of the 256 pulmonary congestion exacerbation in this patient. 257

258 Complications of HFpEF resulting from HBOT have not been previously reported, although 259 this finding is important as HFpEF is more prevalent among older adults, women, and those with 260 obesity, systemic arterial hypertension, diabetes mellitus, and renal dysfunction (29). Given the 261 aging population and the increased medical complexity of patients seen in modern hyperbaric 262 centres, the authors expect an increasing frequency of HBOT candidates with HFpEF in the 263 hyperbaric medicine setting.

264

265 **Clinical implications**

Our data suggest that a minority of patients with HF, regardless of EF, may develop acute 266 heart failure symptoms. However, we also show that this event is rare and potentially 267 preventable, and that these patients can complete HBOT safely after therapy optimization, with 268 close surveillance before and after each session. Cardiac guidelines recommend the use of loop 269 270 diuretics in patients with HFpEF and HFrEF, aiming to reduce symptoms of congestion (18, 20). In 271 our study, no complications were observed among 21 patients out of 23. Interestingly, all but one of these patients were either on therapy with loop diuretics or receiving regular dialysis. It is 272 273 possible that optimizing medical therapy (e.g., initiating or titrating loop diuretics) for patients 274 with HFpEF may avoid or further limit pulmonary congestion in the setting of HBOT.

275 Some HF patients may present for HBOT without the typical history of HF symptoms and 276 low LVEF, well known to physicians as pathognomonic of HFrEF. Indeed, HFpEF is diagnostically 277 challenging for a clinician, given the frequency of atypical symptoms and/or an unremarkable 278 LVEF. In our study, 54% of patients with HFpEF did not have a prior hospitalization primarily

caused by their HF, and the diagnosis was based on transthoracic echocardiogram and signs and/or symptoms of HF while undergoing investigations for other indications (e.g., acute coronary syndrome, or additional tests required during dialysis or diabetes management).

Therefore, even in the absence of a known impairment in LVEF, particular attention to any changes in the patient's clinical condition and pharmacological management during HBOT is warranted, and even mild-to-moderate respiratory or cardiac symptoms during HBOT should trigger further investigation to rule out an acute or subacute episode of HF. Patients with multiple comorbidities treated with numerous medications should be aware that any changes in their medications during HBOT should be discussed with their hyperbaric physician.

For the same reason, the availability of a baseline echocardiogram to facilitate evaluation of diastolic dysfunction during the initial assessment, rather than relying on other tests traditionally performed prior to HBOT (e.g., electrocardiogram or chest x-ray), may further reduce the risk of patients with unrecognized HF developing symptoms in the context of HBOT. However, there is currently a paucity of evidence to define the feasibility or cost-effectiveness of routine cardiac screening before HBOT to prevent these complications.

Finally, both patients who experienced HBOT-related HF in our study developed symptoms after several treatment sessions, rather than after the first one, suggesting the possibility of a cumulative effect of HBOT on pulmonary congestion (rather than acute onset, severe pulmonary edema in a patient who is incidentally referred for HBOT on the brink of this complication). This observation warrants particular consideration in the care of HF patients undergoing HBOT: despite undergoing several uneventful treatment sessions, these patients may

gradually worsen, and still require close surveillance for the entire duration of treatment. Further
 research is needed to characterize the optimal management of patients with HF undergoing
 HBOT.

303

304 Limitations

Our retrospective study has several inherent limitations. Because we retrospectively 305 reviewed health records already compiled at the time of HBOT, it is possible that not all pertinent 306 307 risk factors were identified and recorded. Our data relate to a cohort of patients treated in two 308 urban centres, potentially limiting their generalizability to other settings; similarly, patients were treated by several different healthcare professionals at these settings, limiting consistency in 309 measurement and reporting. Importantly, our study design cannot appreciate patients with HF 310 who may have been referred for HBOT, assessed, and considered to be at too great a risk to 311 312 proceed with treatment. Additionally, due to the rarity of patients with HF undergoing HBOT, we 313 report on a small sample size, limiting estimates of the incidence of HF exacerbation related to HBOT, and subgroup analyses (e.g., stratified by EF %) present data on even smaller groups of 314 315 patients. Finally, the primary outcome of the study was observational, and while two patients experienced symptoms of acute HF following HBOT with a close temporal relationship this cannot 316 317 prove a causative relationship, especially considering the presence of possible confounding variables (e.g., types of and adherence to diuretics, changes in treatment pressure, and 318 positioning after the complication). 319

320

321 Conclusion

Patients with a history of heart failure, whether HFpEF or HFrEF, may develop symptoms of pulmonary congestion during or after HBOT. However, they can safely complete HBOT following medical optimization with close attention paid to any clinical or pharmacological changes during treatment. Identifying patients at risk of HF exacerbation, and taking these measures to prevent acute symptoms during treatment, is an important objective of the pre-HBOT medical assessment.

329 **References**

- 1. Moon R UHMS. Hyperbaric Oxygen Therapy Indications. 14th, ed2019.
- 331 2. Jain KK. Indications, Contraindications, and Complications of HBO Therapy. In: Jain KK, editor.
- 332 Textbook of Hyperbaric Medicine: Springer; 2017. p. 79-84.
- 333 3. Shupak A, Gilbey P. Effects of Pressure. Physiology and Medicine of Hyperbaric Oxygen

334 Therapy2008. p. 513-26.

4. Heyboer M, 3rd, Wojcik SM, Grant WD, Chambers P, Jennings S, Adcock P. Middle ear

barotrauma in hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41(5):393-7.

337 5. Heyboer M, 3rd, Sharma D, Santiago W, McCulloch N. Hyperbaric Oxygen Therapy: Side Effects

338 Defined and Quantified. Adv Wound Care (New Rochelle). 2017;6(6):210-24.

339 6. Weaver LK, Churchill S. Pulmonary edema associated with hyperbaric oxygen therapy. Chest.
340 2001;120(4):1407-9.

341 7. Mathieu D, Favory R, Collet F, Linke J-C, Wattel F. Physiologic Effects of Hyperbaric Oxygen on

342 Hemodynamics and Microcirculation. Handbook on Hyperbaric Medicine: Springer-Verlag; 2006. p. 75-

343 101.

344 8. Whalen RE, Saltzman HA, Holloway DH, Jr., McIntosh HD, Sieker HO, Brown IW, Jr.

Cardiovascular and Blood Gas Responses to Hyperbaric Oxygenation. Am J Cardiol. 1965;15(5):638-46.

346 9. Pisarello JB CJ, Lambertsen CJ, Gelfand R, editor Human circulatory responses to prolonged

- 347 hyperbaric hyperoxia in Predictive Studies V. Proceedings of the Ninth International Symposium on
- 348 Underwater and Hyperbaric Physiology, Undersea and Hyperbaric Medical Society; 1987.
- 10. Pelaia P RM, Conti G, De Blasi RA, Bufi M, Antonelli M, Bortone C. Hemodynamic modifications
- during hyperbaric oxygen therapy. J Hyperb Med. 1992;7(4):229-37.

- McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, et al. Nitric oxide in
 the human respiratory cycle. Nat Med. 2002;8(7):711-7.
- 353 12. Weaver LK, Howe S, Snow GL, Deru K. Arterial and pulmonary arterial hemodynamics and
- 354 oxygen delivery/extraction in normal humans exposed to hyperbaric air and oxygen. J Appl Physiol
- 355 (1985). 2009;107(1):336-45.
- 13. Nakada T, Koike H, Katayama T, Watanabe H, Yamori Y. Increased adrenal epinephrine and
- 357 norepinephrine in spontaneously hypertensive rats treated with hyperbaric oxygen. Hinyokika kiyo Acta
- 358 urologica Japonica. 1984;30(10):1357-66.
- 14. Heyboer Rd M, Wojcik SM, Smith G, Santiago W. Effect of hyperbaric oxygen therapy on blood
- 360 pressure in patients undergoing treatment. Undersea Hyperb Med. 2017;44(2):93-9.
- 15. Schiavo S, Djaiani C, DeBacker J, Albertini L, Santa Mina D, Buryk-Iggers S, et al. Magnitude and
- 362 Clinical Predictors of Blood Pressure Changes in Patients Undergoing Hyperbaric Oxygen Therapy: A
- 363 Retrospective Study. Int J Environ Res Public Health. 2020;17(20).
- 16. Molenat F, Boussuges A, Grandfond A, Rostain JC, Sainty JM, Robinet C, et al. Haemodynamic
- 365 effects of hyperbaric hyperoxia in healthy volunteers: an echocardiographic and Doppler study. Clin Sci
- 366 (Lond). 2004;106(4):389-95.
- 17. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017
- 368 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart
- 369 Failure. Can J Cardiol. 2017;33(11):1342-433.
- 18. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC
- 371 Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J.
- 372 2021;42(36):3599-726.
- 19. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal
- definition and classification of heart failure: a report of the Heart Failure Society of America, Heart

- 375 Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing
- 376 Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure.
- 377 2021;23(3):352-80.
- 20. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA
- 379 Guideline for the Management of Heart Failure: A Report of the American College of
- 380 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation.
- 381 2022;145(18):e895-e1032.
- 382 21. Gazewood JD, Turner PL. Heart Failure with Preserved Ejection Fraction: Diagnosis and
- 383 Management. Am Fam Physician. 2017;96(9):582-8.
- 384 22. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology,
- diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9.
- 386 23. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med.
- 387 2004;351(11):1097-105.
- 388 24. Kenmure AC, Murdoch WR, Hutton I, Cameron AJ. Hemodynamic effects of oxygen at 1 and 2
- Ata pressure in healthy subjects. J Appl Physiol. 1972;32(2):223-6.
- 25. Leitman M, Efrati S, Fuchs S, Hadanny A, Vered Z. The effect of hyperbaric oxygenation therapy
- on myocardial function. Int J Cardiovasc Imaging. 2020;36(5):833-40.
- 26. Li Y, Hao Y, Wang T, Wei L, Wang W, Liang Y, et al. The Effect of Hyperbaric Oxygen Therapy on
- 393 Myocardial Perfusion after the Implantation of Drug-Eluting Stents. Ann Clin Lab Sci. 2018;48(2):158-63.
- 27. Aparci M, Kardesoglu E, Suleymanoglu S, Uzun G, Onem Y, Uz O, et al. Hyperbaric oxygen
- therapy improves myocardial diastolic function in diabetic patients. Tohoku J Exp Med. 2008;214(3):281-

396 9.

- 397 28. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling
- 398 pressures in patients with and without congestive heart failure. Chest. 2001;120(2):467-73.

- 29. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart
- 400 failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus
- 401 recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
- 402 Eur J Heart Fail. 2020;22(3):391-412.

403

405 Supporting information

- 406 **S1 Table. Approved Indications for Hyperbaric Oxygen Therapy in Canada and the United**
- 407 **States.** Hyperbaric oxygen therapy indications approved by Health Canada (*) or the US Food
- 408 and Drug Administration (†). Unlabeled items are approved by both agencies.